Blocking One Immune Receptor May Halt Widespread Aging

Imagine the body as a city where garbage trucks stop running. Trash piles up. Streets clog. Everything slows down. That image may explain a surprising part of why we age: our long-lived immune cells, the local “sanitation crew” of each organ, lose their appetite for decay and let inflammatory debris accumulate.

Researchers at Stanford traced this failure to tissue-resident macrophages — cells born early in life that settle inside organs and quietly clear away spent or damaged cells. In mice, switching off a single inflammatory receptor on these macrophages restored their cleanup work and preserved function across many organs: brain, heart, liver, kidneys, colon, spleen, bone marrow and muscle. The finding, published in Science, reads like a biology detective story. One molecular change. Widespread consequences.

Why would one receptor matter so much? Start with neutrophils. These are the immune system’s kamikaze first responders: fast, destructive and very short-lived. Most live only a day or less. The body must remove roughly a hundred billion of them every 24 hours. That clearance happens mainly in organs rich in tissue-resident macrophages — the liver, spleen and bone marrow.

But when the cleanup falters, trouble ensues. Neutrophils that overstay their welcome slide into senescence: they stop working properly, yet still pump out inflammatory signals that injure neighbors and nudge other cells toward aging. In short: old, half-dead immune cells become a source of chronic damage.

Macrophages normally gobble these failing neutrophils and keep tissues tidy. With age, macrophages themselves weaken. Metabolism wanes. Their responsiveness shifts toward persistent inflammation. The Stanford team homed in on one culprit in that shift: an EP2 receptor that amplifies a prostaglandin signal called PGE2. PGE2 rises during infection, injury and with age. If macrophages express more EP2, they become hypersensitive to the signal. A vicious loop forms: more PGE2 plus more EP2 equals poorer macrophage metabolism, fewer neutrophils cleared, and more inflammation.

So the scientists did what any good mechanic would do — they tested whether removing the faulty part fixes the engine. They engineered mice in which the EP2 gene could be selectively deleted only in tissue-resident macrophages, and only at chosen times. The result was striking. Macrophages regained their capacity to engulf aging neutrophils. Senescent neutrophil numbers fell toward youthful levels. And the benefits were not limited to one organ.

The team measured 71 blood proteins that shift with age; in EP2-deficient animals, 59 of those proteins stayed at young-animal levels. Many of those proteins came from the liver — a metabolic command center that depends heavily on resident macrophages. EP2-free mice were leaner, carried less visceral fat, retained more muscle, and showed stronger performance on balance, grip and memory tests. Even the hippocampus, a brain region central to navigation and recall, showed reduced inflammation and improved function.

Does blocking EP2 work pharmacologically as well as genetically? The researchers treated 22-month-old mice — roughly comparable to humans in their 60s or 70s — with an experimental EP2 inhibitor for two months. The drug nudged neutrophil counts and senescent markers back toward youth, and in cell culture it restored aged macrophages’ appetite for dead neutrophils. It’s early, but proof-of-concept is clear: targeting EP2 can revive an exhausted cleanup crew.

Human relevance matters. Mining a large single-cell atlas of human livers, the team found the same pattern seen in mice: older livers had more neutrophils, greater neutrophil senescence, weakened resident macrophage activity and heightened EP2 signaling — changes amplified in diseased livers. It’s the first time this full molecular picture has been laid out in human tissue, and it suggests the pathway is not a mouse-only quirk.

This work reframes an old question. Instead of treating late-life disease as a collection of independent problems — heart failure here, cognitive decline there — what if a shared breakdown in immune cleanup seeds damage across tissues? One failing mechanism could cascade into many symptoms. That idea shifts therapeutic strategy from broadly suppressing inflammation to restoring the immune system’s ability to remove its own sources of harm.

There are caveats. No approved drug today selectively blocks EP2 without disturbing other prostaglandin pathways. Classic anti-inflammatories blunt PGE2 production wholesale, which can relieve pain but also interfere with useful prostaglandin functions. The promise here is precision: blunt the harmful EP2 branch while leaving other prostaglandin signaling intact.

As Katrin Andreasson, the study’s senior author, put it: “We’ve been trying to figure out why we age. Now we know at least one big reason for it.”

Translating this into a safe, long-term therapy for people remains a challenge. But the path is clearer now: restore the body’s garbage collectors rather than muzzling inflammation globally. If that approach pans out, it could change how we think about aging — not as inevitable breakdown, but as a recoverable failure of maintenance — and prompt the search for drugs that tune cleanup rather than silence it.